Molecular Diagnostics News and Research

RSS

Co-Diagnostics obtains CE mark approval for Logix Smart MTB Test

Co-Diagnostics, Inc., a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostic tests, announced today that its Logix Smart™ MTB Test has obtained CE mark approval, the principle regulatory clearance allowing the test to be sold as an in vitro diagnostic for the diagnosis of tuberculosis in European Union states and other markets that accept a CE-IVD mark as valid regulatory approval.

25 Jul 2018

Study: Blood test can predict response of advanced prostate cancer patients to treatments

An international collaborative study between Lawson Health Research Institute, Memorial Sloan Kettering Cancer Center, the Royal Marsden and Epic Sciences is one of the first to demonstrate that a blood test can predict how patients with advanced prostate cancer will respond to specific treatments, leading to improved survival.

25 Jul 2018

OGT announces direct sales and support services in Europe

Oxford Gene Technology, The Molecular Genetics Company, has announced that it is now directly selling Cytocell Fluorescence In Situ Hybridisation products through several established affiliates of SysmexCorporation in Europe following its acquisition last year.

From Oxford Gene Technology 4 Jul 2018

Innovative concept for implementing WHO resolution to safeguard quality of cancer treatment

Cancer is a burden to those affected by it and a growing challenge to the political sector. In 2017, WHO therefore issued an international resolution to safeguard the quality of cancer treatment, and access to it, in every country in the world.

14 Jun 2018

Agendia and Angsana partner to market MammaPrint, BluePrint breast cancer tests in Southeast Asia

Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, and Angsana Molecular & Diagnostics Laboratory Pte Ltd, a subsidiary of Parkway Pantai, announce a partnership to market the MammaPrint Breast Cancer Risk of Recurrence test and the BluePrint Molecular Subtyping test to physicians across Southeast Asia, including Singapore, Malaysia, Vietnam, Brunei and Myanmar.

31 May 2018

Study identifies new biomarker for early lung cancer diagnosis

High levels of cytoskeleton-associated protein 4 (CKAP4) have been identified in the blood of patients with lung cancer.

8 May 2018

New data supports clinical use of DecisionDx-Melanoma test to inform SLNB options

Castle Biosciences, Inc., the skin cancer diagnostics company providing molecular diagnostics to improve cancer treatment decisions, today announced the presentation of data supporting clinical use of the DecisionDx®-Melanoma test to inform sentinel lymph node biopsy (SLNB) recommendations.

7 May 2018

Tradeshow Talks with Molbio Diagnostics Ltd

Tradeshow Talks with Molbio Diagnostics Ltd at Health GB 2018.

7 May 2018

New, sensitive HBV assay may allow earlier detection of hepatocellular carcinoma

Chronic hepatitis B virus (HBV) can progress to cirrhosis and hepatocellular carcinoma (HCC). A study published in The Journal of Molecular Diagnostics describes a new HBV assay that offers advantages over currently used methods because it has the capability to detect closed circular DNA (cccDNA) in serum, single cells, and preserved tissue samples.

12 Apr 2018

Oxford Gene Technology announces leadership changes

Oxford Gene Technology, The Molecular Genetics Company, has announced that on 1st April 2018 Dr John Anson who has been with the company since 2006 as EVP of R&D took over as CEO from Dr Mike Evans, who has become a non-executive director of OGT’s board.

From Oxford Gene Technology 10 Apr 2018

Technological advances in biosensors could reduce spread of HIV infection

1.8 million people acquire HIV each year, with the World Health Organisation estimating that 1 in 5 people living with HIV do not realize they are infected. Therefore, strategies for faster and earlier diagnosis are as important as ever to limit the spread of HIV.

From IDTechEx Ltd 7 Mar 2018

Myriad Genetics shows strong commitment, support in the fight against colorectal cancer

Myriad Genetics, Inc., a leader in molecular diagnostics and personalized medicine, continues to demonstrate an unmatched commitment to hereditary cancer risk assessment and genetic testing during National Colorectal Cancer Awareness Month.

2 Mar 2018

Using Smartphones for Cancer Diagnosis and Management

Dr. Castro is a translational oncologist with experience developing and harnessing nanotechnology and molecular imaging platforms for cancer purposes. His work offers a “less is more” approach — to generate robust cancer analyses using scant amount of specimens. Dr. Castro’s research has included funding from the V Foundation for Cancer Research, National Institutes of Health, Ovarian Cancer Research Fund, and the Department of Defense.

From Pittcon 14 Feb 2018

Myriad’s myRisk Hereditary Cancer test finds inherited gene mutations in more than 12% of prostate cancer patients

Myriad Genetics, Inc., a leader in molecular diagnostics and personalized medicine, announced today that results from a large 1,162 patient study of the Myriad myRisk Hereditary Cancer test will be featured during the poster presentation at the 2018 Genitourinary Cancer Symposium in San Francisco, Calif.

8 Feb 2018

Leading medical societies update molecular testing guideline for lung cancer

Rapid advancements in the molecular diagnostic testing of lung cancer have led to new treatments and greater hope for patients battling lung cancer, the most common cause of cancer death worldwide.

24 Jan 2018

Experts issue updated guidelines for molecular diagnostic testing of patients with lung cancer

A panel of leading experts in molecular pathology has issued new recommendations and updates to guidelines for molecular diagnostic testing of patients with lung cancer.

23 Jan 2018

Mobidiag introduces new fully automated diagnostic solution for infectious diseases

Mobidiag, a Finnish molecular diagnostics company, launches Novodiag, a fully automated solution for syndromic and targeted testing of infectious diseases, supporting limitation of antibiotic use.

4 Jan 2018

Myriad Genetics announces new data on EndoPredict test at 2017 San Antonio Breast Cancer Symposium

Myriad Genetics, Inc., a leader in molecular diagnostics and personalized medicine, today announced new results from two studies with EndoPredict are being featured at the 2017 San Antonio Breast Cancer Symposium in San Antonio, Texas.

12 Dec 2017

Simple molecular test may help predict presence of high-grade pancreatic cancers

A report in The Journal of Molecular Diagnostics, describes a new simple molecular test to detect chromosomal abnormalities -- biomarkers known as telomere fusions--in pancreatic tumor specimens and pancreatic cyst fluids.

8 Dec 2017

Novel gene expression signature assay could help enhance lymphoma management

Diffuse large B-cell lymphoma (DLBCL) is an aggressive cancer and the most frequently diagnosed non-Hodgkin lymphoma worldwide (nearly 40% of cases). Recent advancements indicate that both the prognosis and choice of treatment of DLBCL may depend on identifying its molecular subtype.

17 Oct 2017